Skip to main content
main-content
Top

19-12-2011 | Cardiology | Article

Large registry provides insights into Asian-Pacific patients with AF

Abstract

Free abstract

MedWire News: Most Asian-Pacific patients with atrial fibrillation (AF) have at least one cardiovascular disease risk factor, and more than half have hypertension, research shows.

In terms of therapy, rate control is the preferred treatment strategy in these patients, although this approach is more commonly used in patients with persistent AF.

These are some of the observations of baseline patient data taken from a large Asian-Pacific AF registry published in the American Journal of Cardiology.

The analysis, from John Amerena (Deakin University, Victoria, Australia) and colleagues, provides some data on the burden and management of AF in countries from the Asian-Pacific region.

There were 2629 patients from Australia, China, Hong Kong, Korea, Malaysia, the Philippines, Taiwan, and Thailand eligible for analysis. The mean age of AF patients was 64 years and 60% were men.

Hypertension was the most prevalent comorbidity (58%), but dyslipidemia (37%), heart failure (25%), and valvular heart disease (23%) were also common comorbid conditions.

Among the patients with heart failure, 74% were in New York Heart Association functional class I or II.

Of 2629 AF patients, 37% were treated with a rhythm-control treatment and 62% with rate-control therapies. At their baseline visit, 81% of the rhythm-control patients and 88% of the rate-control patients were prescribed thromboembolic prevention therapy.

Rhythm-control patients were treated with class III agents (49%), class Ic drugs (39%), or beta blockers (35%). Patients treated with rate-control drugs were typically prescribed beta blockers (57%), but also received glycosides (32%).

"The presence of co-morbidities did not appear to strongly influence the treatment choice, with the exception that a rate-control strategy was chosen significantly more frequently than rhythm-control strategy for patients with heart failure (31 vs 14%) and valvular heart disease (27 vs 15%)," state Amerena and colleagues.

Sotalol was not prescribed to any of the AF patients.

Compared with a global AF registry, fewer patients assigned to rhythm-control therapy were assigned beta blockers, note the researchers.

MedWire (http://www.medwire-news.md/) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011

By MedWire Reporters

Related topics